Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) Revenue (2016 - 2025)

Dexcom (DXCM) has disclosed Revenue for 16 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 13.12% to $1.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.7 billion, a 15.6% increase, with the full-year FY2025 number at $4.7 billion, up 15.6% from a year prior.
  • Revenue was $1.3 billion for Q4 2025 at Dexcom, up from $1.2 billion in the prior quarter.
  • In the past five years, Revenue ranged from a high of $1.3 billion in Q4 2025 to a low of $505.0 million in Q1 2021.
  • A 5-year average of $883.8 million and a median of $896.2 million in 2023 define the central range for Revenue.
  • Peak YoY movement for Revenue: surged 31.72% in 2021, then increased 1.97% in 2024.
  • Dexcom's Revenue stood at $698.2 million in 2021, then grew by 16.76% to $815.2 million in 2022, then rose by 26.9% to $1.0 billion in 2023, then grew by 7.64% to $1.1 billion in 2024, then grew by 13.12% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Revenue are $1.3 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.2 billion (Q2 2025).